UNSPSC 51282415: Carbenicillin indanyl sodium

This classification denotes an extended spectrum penicillin antibiotic with the molecular formula C26H25N2O6S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4OUL81K2RT, chemically known as 1-(5-indanyl)(2s,5r,6r)-n-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)hept-6-yl)-2-phenylmalonamate monosodium salt, but more generally known as carbenicillin indanyl sodium, which bears US NIH Compound Identifier 33554.

UNSPSC 51282415 Carbenicillin indanyl sodium, a Commodity code, shows a fundamental mismatch between its nominal scope and current state and local procurement activity. The code identifies a specific antibiotic pharmaceutical, but the recent opportunities posted under it span medical and first aid supplies, naloxone and drug deactivation systems, generic multi-source pharmaceuticals and OTC products, and direct-to-manufacturer prescription programs — none of which directly involve carbenicillin indanyl sodium. State and local governments are soliciting broadly across pharmacy benefit management, emergency medical supplies, and drug procurement infrastructure, not narrowly specified pharmaceutical molecules.

The issuing bodies include city purchasing departments (City of Tampa), county health agencies (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (Minnesota MMCAP, serving multiple states including Oregon). Representative recent solicitations include Tampa Fire Department's IFB for 169 line items of medical and first aid supplies with a $700 million estimated value and an SLBE set-aside (response deadline March 13, 2026); Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (response deadline July 26, 2023); MMCAP's RFP for generic multi-source pharmaceuticals and OTC products across participating state and local facilities, due March 26, 2026; and the Texas HHS RFI regarding direct-to-manufacturer prescription programs (response deadline April 3, 2026). The geographic spread includes Florida, Texas, Minnesota, and Oregon. The code shows little activity aligned with its specified commodity — the tagging appears to reflect broader pharmaceutical procurement categories rather than demand for this particular drug molecule.